XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]              
Cash dividend (in dollars per share) $ 0.16 $ 0.16 $ 0.16 $ 0.16      
Cash dividend paid         $ 7,600,000    
Treasury stock acquired (in shares)         0 0  
Granted (in shares)         0 307,000  
Weighted average grant date fair value (in dollars per share)           $ 12.29  
Expiration period           10 years  
Vesting period           5 years  
Award vesting rights, percentage           20.00%  
Fair value of options granted (in dollars per share)           $ 1.76  
Risk-free interest rate           0.60%  
Expected term           6 years 6 months  
Expected volatility           65.21%  
Dividend yield           4.85%  
Compensation cost not yet recognized $ 516,600       $ 516,600 $ 719,600  
Aggregate intrinsic value, exercisable 2,000,000       2,000,000 1,000,000  
Aggregate intrinsic value, outstanding $ 4,000,000       $ 4,000,000 $ 2,300,000  
Corporate Joint Venture | PDL LLC              
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]              
Ownership percentage 0.00%       0.00%   51.00%
Common Stock Options              
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]              
Cost not yet recognized, period for recognition         2 years 9 months 18 days 3 years 10 months 24 days  
2020 Equity Incentive Plan | Common Stock Options              
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]              
Number of shares authorized to be purchased (in shares) 935,000       935,000    
Number of remaining shares available for grant (in shares) 628,000       628,000    
2020 Equity Incentive Plan | Restricted Stock              
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]              
Number of shares authorized to be purchased (in shares) 55,000       55,000    
Number of remaining shares available for grant (in shares) 51,794       51,794    
Vesting period         5 years    
Granted (in shares)         3,206 1,982  
Vested and exercised (in shares)         1,880 1,241  
Nonvesting restricted stocks (in shares) 4,693       4,693 3,367  
Weighted average of grant date fair value (in dollars per share)         $ 15.60 $ 25.23  
Share-based compensation expense         $ 32,006,000 $ 21,300,000